Refine
Has Fulltext
- yes (14)
Is part of the Bibliography
- yes (14)
Document Type
- Journal article (14)
Language
- English (14)
Keywords
- radioligand therapy (4)
- CXCR4 (3)
- PSMA (3)
- prostate cancer (3)
- theranostics (3)
- C-X-C motif chemokine receptor 4 (2)
- PET (2)
- PET/CT (2)
- [68Ga]PentixaFor (2)
- endoradiotherapy (2)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- COVID-19 (1)
- CTCAE (1)
- CXCR4-targeting (1)
- MIBG (1)
- NEC (1)
- NET (1)
- PRRT (1)
- PSA (1)
- PSMA-RADS (1)
- RADS (1)
- RLT (1)
- SARS-CoV-2 (1)
- SSTR-RADS (1)
- SUV (1)
- [177Lu]/[90Y]PentixaTher (1)
- [177Lu]Lu-PSMA I&T (1)
- [177Lu]PentixaTher (1)
- [90Y]PentixaTher (1)
- [\(^{68}\)Ga]Ga-FAPI (1)
- \(^{177}\)Lu (1)
- \(^{18}\)F-PSMA-1007 (1)
- adrenocortical carcinoma (1)
- angiogenesis (1)
- blood flow (1)
- cardiac nerve (1)
- combination (1)
- fibroblast activation protein (1)
- flare phenomenon (1)
- hematotoxicity (1)
- immune infiltration (1)
- inflammation (1)
- late response (1)
- mRNA (1)
- machine learning (1)
- miRNA (1)
- molecular imaging (1)
- multiple myeloma (1)
- nephrotoxicity (1)
- neuroendocrine tumor (1)
- overall survival (1)
- papillary thyroid carcinoma (PTC) (1)
- peptide receptor radionuclide therapy (1)
- prediction (1)
- radioiodine (1)
- reporting and data system (1)
- selpercatinib (1)
- staging (1)
- standardized reporting system (1)
- statin (1)
- sympathetic nervous system (1)
- thyroid carcinoma (TC) (1)
- transcriptome (1)
- tumor microenvironment (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (14)
- Urologische Klinik und Poliklinik (5)
- Medizinische Klinik und Poliklinik I (4)
- Medizinische Klinik und Poliklinik II (3)
- Comprehensive Cancer Center Mainfranken (2)
- Pathologisches Institut (2)
- Center for Computational and Theoretical Biology (1)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (1)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (1)
(1) Background: C-X-C Motif Chemokine Receptor 4 (CXCR4) and Fibroblast Activation Protein Alpha (FAP) are promising theranostic targets. However, it is unclear whether CXCR4 and FAP positivity mark distinct microenvironments, especially in solid tumors. (2) Methods: Using Random Forest (RF) analysis, we searched for entity-independent mRNA and microRNA signatures related to CXCR4 and FAP overexpression in our pan-cancer cohort from The Cancer Genome Atlas (TCGA) database — representing n = 9242 specimens from 29 tumor entities. CXCR4- and FAP-positive samples were assessed via StringDB cluster analysis, EnrichR, Metascape, and Gene Set Enrichment Analysis (GSEA). Findings were validated via correlation analyses in n = 1541 tumor samples. TIMER2.0 analyzed the association of CXCR4 / FAP expression and infiltration levels of immune-related cells. (3) Results: We identified entity-independent CXCR4 and FAP gene signatures representative for the majority of solid cancers. While CXCR4 positivity marked an immune-related microenvironment, FAP overexpression highlighted an angiogenesis-associated niche. TIMER2.0 analysis confirmed characteristic infiltration levels of CD8+ cells for CXCR4-positive tumors and endothelial cells for FAP-positive tumors. (4) Conclusions: CXCR4- and FAP-directed PET imaging could provide a non-invasive decision aid for entity-agnostic treatment of microenvironment in solid malignancies. Moreover, this machine learning workflow can easily be transferred towards other theranostic targets.
Prostate-specific membrane antigen (PSMA)-directed positron emission tomography/computed tomography (PET/CT) is increasingly utilized for staging of men with prostate cancer (PC). To increase interpretive certainty, the standardized PSMA reporting and data system (RADS) has been proposed. Using PSMA-RADS, we characterized lesions in 18 patients imaged with \(^{18}\)F-PSMA-1007 PET/CT for primary staging and determined the stability of semi-quantitative parameters. Six hundred twenty-three lesions were categorized according to PSMA-RADS and manually segmented. In this context, PSMA-RADS-3A (soft-tissue) or -3B (bone) lesions are defined as being indeterminate for the presence of PC. For PMSA-RADS-4 and -5 lesions; however, PC is highly likely or almost certainly present [with further distinction based on absence (PSMA-RADS-4) or presence (PSMA-RADS-5) of correlative findings on CT]. Standardized uptake values (SUV\(_{max}\), SUV\(_{peak}\), SUV\(_{mean}\)) were recorded, and volumetric parameters [PSMA-derived tumor volume (PSMA-TV); total lesion PSMA (TL-PSMA)] were determined using different maximum intensity thresholds (MIT) (40 vs. 45 vs. 50%). SUV\(_{max}\) was significantly higher in PSMA-RADS-5 lesions compared to all other PSMA-RADS categories (p ≤ 0.0322). In particular, the clinically challenging PSMA-RADS-3A lesions showed significantly lower SUV\(_{max}\) and SUV\(_{peak}\) compared to the entire PSMA-RADS-4 or -5 cohort (p < 0.0001), while for PSMA-RADS-3B this only applies when compared to the entire PSMA-RADS-5 cohort (p < 0.0001), but not to the PSMA-RADS-4 cohort (SUV\(_{max}\), p = 0.07; SUV\(_{peak}\), p = 0.08). SUV\(_{mean}\) (p = 0.30) and TL-PSMA (p = 0.16) in PSMA-RADS-5 lesions were not influenced by changing the MIT, while PSMA-TV showed significant differences when comparing 40 vs. 50% MIT (p = 0.0066), which was driven by lymph nodes (p = 0.0239), but not bone lesions (p = 0.15). SUV\(_{max}\) was significantly higher in PSMA-RADS-5 lesions compared to all other PSMA-RADS categories in \(^{18}\)F-PSMA-1007 PET/CT. As such, the latter parameter may assist the interpreting molecular imaging specialist in assigning the correct PSMA-RADS score to sites of disease, thereby increasing diagnostic certainty. In addition, changes of the MIT in PSMA-RADS-5 lesions had no significant impact on SUV\(_{mean}\) and TL-PSMA in contrast to PSMA-TV.